Table 1 Population characteristics.

From: Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial

 

N = 70 (%)

Sex M/F

34/36

Median Age (range

55 (18–73)

Disease

 - AML

39 (56.5%)

 - CML

3 (4.3%)

 - Lymphoma

9 (13%)

 - Bone marrow failure

2 (2.8%)

 - MDS/MPN

16 (23.1%)

CONDITIONING

 TBI

13 (18,8%)

 Myeloablative

18 (26%)

HLA matching

 - Identical sibling

12 (17.3%)

 - Unrelated 10/10

44 (63.7%)

 - Mismatched unrelated

13 (18.8%)

Acute GVHD

 - Grade I

16 (23.1%)

 - Grade II

21 (30.4%)

 - Grade III

17 (24.6%)

 - Grade IV

10 (14.4%)

Chronic GVHD

33 (47.8%)

CMV status

 Positive

37 (53.6%)

 negative

32 (46.3%)

Median BMI (range) kg/m²

23.9

(16–44.9)

Median SGA (range)

2

(0–22)

Median Albuminemia (range) g/L

43

(28–54)

Median Préalbuminemia (range) Mmol/L

0.282

(0.165–0.499)

Median Handsgrip (range) kg

30

(14–54)

Median brachial circumference (range) cm

30

(21–40)

Median EVA appetite (range)

10

(2–10)